The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 1.22M shares traded hands or 73.35% up from the average. Insys Therapeutics Inc (NASDAQ:INSY) has declined 23.22% since April 8, 2016 and is downtrending. It has underperformed by 28.86% the S&P500.
The move comes after 9 months positive chart setup for the $1.16B company. It was reported on Nov, 10 by Barchart.com. We have $20.80 PT which if reached, will make NASDAQ:INSY worth $568.40M more.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. JMP Securities maintained it with “Market Outperform” rating and $30 target price in Wednesday, March 9 report. As per Thursday, April 14, the company rating was initiated by Janney Capital. The rating was maintained by Jefferies with “Buy” on Thursday, August 4. The firm has “Buy” rating by Zacks given on Friday, August 14. The company was maintained on Tuesday, August 4 by Oppenheimer. On Tuesday, April 12 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Buy” rating on Monday, October 10 by Jefferies. Jefferies maintained the stock with “Buy” rating in Wednesday, February 24 report. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Outperform” rating given on Thursday, September 22 by RBC Capital Markets.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio dropped, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Healthinvest Partners Ab, a Sweden-based fund reported 788,175 shares. Van Eck Associates Corporation reported 234 shares or 0% of all its holdings. Eqis Mgmt holds 0.08% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 94,774 shares. Community Natl Bank Na has 1,000 shares for 0% of their US portfolio. The New York-based Art Advsrs Ltd Limited Liability Company has invested 0.03% in Insys Therapeutics Inc (NASDAQ:INSY). Proshare Advisors Limited has invested 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Jpmorgan Chase And owns 88 shares or 0% of their US portfolio. Adage Cap Prtn Grp Ltd Co holds 0.01% or 275,000 shares in its portfolio. Fmr Limited Liability Corporation has 0% invested in the company for 794,645 shares. Clinton Gp accumulated 17,368 shares or 0.01% of the stock. Pacad Inv Limited owns 14,900 shares or 0.03% of their US portfolio. Alps Advisors Inc holds 22,449 shares or 0% of its portfolio. California State Teachers Retirement accumulated 49,044 shares or 0% of the stock. The California-based Blackrock Fund Advisors has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Panagora Asset Mngmt holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 1,359 shares.
Insider Transactions: Since May 11, 2016, the stock had 2 insider purchases, and 4 sales for $704,930 net activity. STANLEY THEODORE H had sold 15,000 shares worth $270,300 on Tuesday, August 16. On Friday, August 12 JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 bought $105,853 worth of the stock or 5,700 shares. On Friday, November 4 MEYER STEVEN J bought $107,489 worth of the stock or 10,000 shares. $110,752 worth of shares were sold by BRENNAN DANIEL on Tuesday, August 9. 15,000 shares were sold by FOURTEAU PATRICK, worth $276,900.
Another recent and important Insys Therapeutics Inc (NASDAQ:INSY) news was published by Forbes.com which published an article titled: “Insys Therapeutics Pops On Earnings Beat, But Revenues Plunge” on November 03, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.